Evidence map›Paper›PMID 40788756›Full record

ArticleAmerican journal of respiratory and critical care medicine2026

Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes.

Eckart De Bie, Priscilla Correa-Jaque, Rowena Jones, Harm J Bogaard, Justine Chan, Colin Church, John G Coghlan, Akshay Gaur, Stefano Ghio, Hossein-Ardeschir Ghofrani and 21 more

Abstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Frailty in Pulmonary Arterial Hypertension: A Cohort Study.Annals of the American Thoracic Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Eckart De BieVictor Phillip Dahdaleh Heart and Lung Research Institute.ORCID 0000-0002-1595-1226
Priscilla Correa-JaqueMount Sinai Icahn School of Medicine, New York, New York.
Rowena JonesVictor Phillip Dahdaleh Heart and Lung Research Institute.
Harm J BogaardAmsterdam University Medical Center (location VUmc), Amsterdam, the Netherlands.
Justine ChanVictor Phillip Dahdaleh Heart and Lung Research Institute.
Colin ChurchGolden Jubilee National Hospital, Glasgow, United Kingdom.
John G CoghlanRoyal Free Hospital, London, United Kingdom.
Akshay GaurUniversity of Sheffield & Royal Hallamshire Hospital, Sheffield, United Kingdom.
Stefano GhioFondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
Hossein-Ardeschir GhofraniUniversity of Giessen and Marburg Lung Center, Giessen, Germany.
Ze Ming GohUniversity of Sheffield & Royal Hallamshire Hospital, Sheffield, United Kingdom.
Luke S HowardNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0003-2822-210X
Marc HumbertUniversity Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.ORCID 0000-0003-0703-2892
Gabor KovacsLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Allan LawrieNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0003-4192-9505
James LordanFreeman Hospital, Newcastle upon Tyne, United Kingdom.
Wei-Yu LinMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.
Dharshan Neelam-NaganathanUniversity of Sheffield & Royal Hallamshire Hospital, Sheffield, United Kingdom.
Joseph NewmanVictor Phillip Dahdaleh Heart and Lung Research Institute.ORCID 0000-0001-5514-0754
Christopher J RhodesNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Karen ShearesRoyal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.
Olivier SitbonUniversity Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.ORCID 0000-0002-1942-1951
Thomas W WillisCambridge Institute for Therapeutic Immunology and Infectious Disease, Department of Medicine.
Stephen J WortNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Stefan GräfVictor Phillip Dahdaleh Heart and Lung Research Institute.ORCID 0000-0002-1315-8873
David G KielyUniversity of Sheffield & Royal Hallamshire Hospital, Sheffield, United Kingdom.
Raymond L BenzaMount Sinai Icahn School of Medicine, New York, New York.ORCID 0000-0001-9627-6236
Alex RothmanUniversity of Sheffield & Royal Hallamshire Hospital, Sheffield, United Kingdom.
Chris WallaceCambridge Institute for Therapeutic Immunology and Infectious Disease, Department of Medicine.
Mark ToshnerVictor Phillip Dahdaleh Heart and Lung Research Institute.ORCID 0000-0002-3969-6143
ASPIRE Registry, UK PAH Cohort Consortium, UNIPHY Clinical Trials Network

Funding

PHORA-Pulmonary Hypertension Outcome Risk AssessmentR01HL164906 · NHLBI · SENTARA HEALTH · PI RAYMOND Louis Benza · 2022 to 2026
$3.0M
PHORA: A Clinical Decision Support Tool for Patients with Pulmonary Arterial HypertensionR01HL134673 · NHLBI · OHIO STATE UNIVERSITY · PI BENZA, RAYMOND LOUIS · 2017 to 2020
$2.8M
BHF Basic Science Research FS/SBSRF/21/31025British Heart Foundation (BHF SP/12/12/29836British Heart Foundation Clinical Research Training FS/CRTF/22/24390Clinical Research Development 206632/Z/17/ZDepartment of Health and Social CareDutch Federation of University Medical CentersDutch Heart FoundationMedical Research Council MC_UU_00040/01Medical Research Council MR/K020919/1National Cohort of Idiopathic and HeritableNational Institute for Health and Care ResearchNational Institute for Health Research BioResourceNational Institute for Health Research Cardiorespiratory Biomedical Research Centre, Gates Cambridge Trust OPP1144Netherlands Organization for Health Research and DevelopmentNHLBI NIH HHS R01 HL134673NHLBI NIH HHS R01 HL164906NIH HHS R01 HL164906-05NIHRRoyal Netherlands Academy of Sciences CVON-2012-08Royal Netherlands Academy of Sciences CVON-2017-10Royal Netherlands Academy of Sciences CVON-2018-29Sheffield Biomedical Research Centre NIHR203321The Netherlands Organization for Scientific Research NWO-VICI: 918.16.610The Netherlands Organization for Scientific Research NWO-VIDI: 917.18.338Wellcome Trust
6 · The paper itself

Abstract

RATIONALE AND

objectivesInflammation is associated with all types of pulmonary hypertension (PH), both as a known cause and as a putative confounder. The most common marker of inflammation, C-reactive protein (CRP), has not been widely studied in PH. This study set out to clarify if CRP informs clinical endotyping and outcomes.

methodsTime-series clustering of longitudinal CRP concentrations was employed. Clinical differences between clusters were validated in three independent U.K./international cohorts using clinical cutoff values (n = 10,301; U.K. cohort, ASPIRE and FDA cohort). Associations were analyzed with functional and mortality outcomes by linear and Cox regression models including all causes of PH (groups 1-5). To add mechanistic insight, multiomics were interrogated from associated previously published arrays. MEASUREMENTS AND MAIN

resultsPatients were segregated into two stable CRP clusters (median CRP, 2 vs. 6.5 mg/L), with the high cluster exhibiting significantly higher body mass index (BMI) (difference between medians [DBM], 5.4 kg/m2), higher right atrial pressure (DBM, 2 mm Hg), and reduced 6-minute-walk distance (DBM, 55 m). Inflammation was associated with worse survival and comorbidities, higher pulmonary vascular resistance, and smoking status. CRP and BMI were associated with differing inflammatory profiles in proteomic and transcriptomic analyses. Despite the relationship with CRP, higher BMI was associated with improved survival and lower pulmonary vascular resistance and did not negatively affect 6-minute-walk distance treatment-related functional responses.

conclusionsWe establish a relationship between CRP and BMI across all-cause PH, although CRP and BMI are associated with diverging clinical outcomes. Inflammation and obesity are relevant phenotypes for consideration in clinical trial design. Understanding their impacts on outcomes is important for clinical practice.

Indexed as

C-Reactive ProteinHypertension, PulmonaryInflammationObesityAgedBiomarkersBody Mass IndexCohort StudiesFemaleHumansMaleMiddle AgedBiomarkersC-Reactive Proteinbody mass indexC-reactive proteinpulmonary hypertension

Identifiers

PMID40788756
PMCPMC12888913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.